Rheumatoid Arthritis

  • Ilaris 2015 report

    Ilaris 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 31 Pages The 5 Key Questions Addressed by this...

  • Kineret 2015 report

    Kineret 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 22 Pages The 5 Key Questions Addressed by this...

  • Orencia 2015 report

    Orencia 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 22 Pages The 5 Key Questions Addressed by this...

  • Otrexup 2015 report

    Otrexup 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 20 Pages The 5 Key Questions Addressed by this...

  • Rasuvo 2015 report

    Rasuvo 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 22 Pages The 5 Key Questions Addressed by this...

  • Rayos 2015 report

    Rayos 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 26 Pages The 5 Key Questions Addressed by this...

  • Remicade 2015 report

    Remicade 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 30 Pages The 5 Key Questions Addressed by this...

  • Rituxan 2015 report

    Rituxan 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 29 Pages The 5 Key Questions Addressed by this...

  • Simponi 2015 report

    Simponi 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 26 Pages The 5 Key Questions Addressed by this...

  • Xeljanz 2015 report

    Xeljanz 2015 U.S. PROMOTIONAL AUDIT REPORT Published July 2016 • 20 Pages The 5 Key Questions Addressed by this...

  • Actemra 2014 report

    Actemra 2014 U.S. PROMOTIONAL AUDIT REPORT Published July 2015 • 20 Pages The 5 Key Questions Addressed by this...

  • Enbrel 2014 report

    Enbrel 2014 U.S. PROMOTIONAL AUDIT REPORT Published July 2015 • 23 Pages The 5 Key Questions Addressed by this...